This showed that those with HER2+ breast cancer derive a significant DFS benefit from dose intense chemotherapy (HR = 0.54, 95% CI 0.38–0.79) whereas those with HER2− disease do not (HR = 0.98). Here, ERBB2 is linked to breast carcinoma.